

Image-based Analysis of a Human Neurosphere Stem Cell Model for the Evaluation of Potential Neurotoxicants

CORNING

Application Note

Brad Larson¹, Hilary Sherman², Hannah Gitschier²,
Alexandra Wolff³, Wini Luty³

¹BioTek Instruments, Inc., Winooski, Vermont

²Corning Incorporated, Life Sciences, Kennebunk, Maine

³Enzo Life Sciences, Farmingdale, New York

Abstract

Developmental neurotoxicity (DNT) of environmental chemicals has long been identified as a threat to the health of the human population, as the developing nervous system is particularly susceptible to toxicant exposure. The resulting neurological deficits can have long-term effects on families and society both financially and emotionally. Current DNT testing guidelines involve the use of animal models (primarily rodents). The testing strategy incorporates large numbers of animals, which can be extremely time- and cost-intensive – particularly due to the backlog of chemicals needing to be tested (Lein, et al., 2005). This demand, in addition to current and future proposed regulations on the use of animals for testing, makes it imperative that new models be found to reduce animal experimentation while providing a suitable method to test new chemicals.

Three-dimensional (3D) cell models, which incorporate human neural stem cells (hNSCs) aggregated into neurospheres, have been proposed as a viable alternative for DNT testing. The *in vitro* system has the ability to recapitulate the processes of brain development, including proliferation, migration, differentiation, and apoptosis (Salma, et al., 2015). Inclusion of human cells, as opposed to murine, also meets recommendations to circumvent the drawback of species differences between *in vivo* testing and actual exposure effects.

Here we demonstrate the use of a 3D neurosphere model, composed of hNSCs, to conduct toxicity testing of potential neurotoxicants. A spheroid microplate was used to create and maintain cells in the 3D model. 3D neurosphere proliferation, multipotency, along with the continued capacity to differentiate into neurons, astrocytes, and oligodendrocytes was initially validated. Neurotoxicity testing was then performed using neurospheres maintained in the 3D spheroid microplate. Detection of induced levels of oxidative stress, apoptotic, and necrotic activity within treated neurospheres, compared to negative control spheres, was evaluated. Monitoring of cell proliferation, differentiation, multipotency and experimental testing was performed using a novel cell imaging multi-mode reader.

Materials

Equipment

BioTek Cytation™ 5 Cell Imaging Multi-Mode Reader. Cytation 5 is a modular multi-mode microplate reader combined with automated digital microscopy. Filter- and monochromator-based microplate reading are available, and the microscopy module provides up to 60X magnification in fluorescence, brightfield, color brightfield, and phase contrast. The instrument can perform up to four fluorescence imaging channels in a single step. With special emphasis on live-cell assays, Cytation 5 features temperature control to 65°C, CO₂/O₂ gas control, and dual injectors for kinetic assays. Integrated Gen5™ Data Analysis Software controls Cytation 5. The instrument was used to image spheroids using brightfield and fluorescence microscopy, as well as individual differentiated cells plated in two dimensional format.

Cells

StemPro® Neural Stem Cells (Cat. No. A15654) were purchased from Thermo Fisher.

Microplates

384-well black, clear, round bottom Corning® Ultra-Low Attachment spheroid microplates (Corning Cat. No. 3830), 384-well high content imaging film bottom microplates (Corning Cat. No. 4681), and 6-well clear, TC-treated microplates (Corning Cat. No. 3516) were donated by Corning Life Sciences.

Neurotoxicants and Plate Coatings

Mercury (II) Chloride (Sigma Cat. No. 215465), Methylmercury (II) Chloride (Sigma Cat. No. 442534), Hydrogen Peroxide Solution (Sigma Cat. No. 216763), Poly-L-Ornithine (Sigma Cat. No. P3655), and Laminin (Sigma Cat. No. L2020) were purchased from Sigma-Aldrich.

Antibodies

Nestin (human) monoclonal antibody (2C1 3B9) (Enzo Cat. No. ENZ-ABS109-0100), Oct4 monoclonal antibody (9B7) (Enzo Cat. No. ENZ-ABS271-0100), β III-Tubulin monoclonal antibody (TU-20) (Enzo Cat. No. ALX-804-405-C100), GFAP monoclonal antibody (GF2) (Enzo Cat. No. ENZ-30934), Goat anti-mouse IgG1 (ATTO 590 conjugate) (Enzo Cat. No. ALX-211-204TM-C100), and Goat anti-mouse IgG (ATTO 647N conjugate) (Enzo Cat. No. ALX-211-205TS-C100) were donated by Enzo Life Sciences. Anti-oligodendrocyte specific protein antibody (abcam Cat. No. ab53041) was purchased from abcam.

Assay Components

ROS-ID™ Total ROS detection kit (Enzo Cat. No. ENZ-51011), GFP CERTIFIED® Apoptosis/Necrosis detection kit Apoptosis detection reagent (Enzo Cat. No. ENZ-51002), and NUCLEAR-ID® Blue/Red cell viability reagent (GFP Certified) (Enzo Cat. No. ENZ-53005-C100) were donated by Enzo Life Sciences.

Image-based Tracking of Neurosphere Growth

Neural stem cells were propagated on 6-well plates previously coated with Poly-L-Ornithine and Laminin. Cells were then removed and added to wells of a 384-well spheroid microplate at concentrations of 32,000 to 100 cells/well with 12 replicates per concentration. Single neurospheres formed after a 48-hour period. The microplate was inserted into the Cytation™ 5, previously set to 37°C/5% CO₂, and all 384 wells containing spheroids were imaged (Figure 1A). The process was repeated at regular intervals over a 9-day period to determine the ability of neural stem cells to propagate in a 3D configuration.

Brightfield imaging, using a 4X objective, was performed on the spheroid set with the Cytation 5 on day 0 (after spheroid formation was complete) and again after 1, 2, 4, 5, 7, and 9 additional

days of incubation. The cellular analysis capabilities of the Gen5™ Data Analysis Software were used to automatically place object masks around each entire spheroid. Average area inside the masks for the 12 replicate neurospheres, as calculated by the software, was plotted over time (Figure 1B). All neurospheres showed active growth in the spheroid microplate, as shown by an increase in average spheroid area from day 0 to day 9. Fold increases in area compared to original values ranged from a 2X increase for neurospheres initially containing 32,000 cells to a 5X increase for neurospheres initially containing 100 cells.

Neurosphere Proliferation and Multipotency Validation

The ability of neural stem cells, cultured into neurospheres, to maintain high proliferative and multipotency capability was further tested through immunocytochemistry. Nestin is an intermediate filament protein necessary for neural stem cell self-renewal. Oct4 is a transcription factor linked to multipotency in stem cells. Primary antibodies specific for each were added to separate wells containing cultured neurospheres to assay for the two biomarkers. Fluorescently labeled secondary antibodies were then added to the wells, in addition to negative control wells containing no primary antibody.




Figure 1. Imaging and area analysis of 3D neurosphere growth. (A) Thumbnail brightfield images of aggregated neurospheres captured using a 4X objective. Twelve replicates per row of neurospheres formed from neural stem cells dispensed at 32,000, 16,000, 8,000, 4,000, 2,000, 1,000, 500, and 100 cells/well. (B) Plot of average spheroid area per dispensed cell concentration during incubation period as determined by Gen5 Data Analysis Software.




Figure 2. Detection of proliferation and multipotency markers. Overlaid brightfield and fluorescence 20X images of positive and negative control wells. (A) Proliferation positive control: Nestin (human) monoclonal antibody (2C1 3B9) plus goat anti-mouse IgG1 (ATTO 590 conjugate) antibody. (B) Proliferation negative control: Goat anti-mouse IgG1 (ATTO 590 conjugate) antibody alone. (C) Multipotency positive control: Oct4 monoclonal antibody (9B7) plus goat anti-mouse IgG (ATTO 647N conjugate) antibody. (D) Multipotency negative control: Goat anti-mouse IgG (ATTO 647N conjugate) antibody alone. RFP Channel: ATTO 590 goat anti-mouse IgG1; Texas Red Channel: ATTO 647 goat anti-mouse IgG.

Expression of Nestin and Oct4 proliferation and multipotency proteins within 3D cultured neural stem cells is confirmed by the fluorescent signal emanating from primary and secondary antibody binding in Figure 2A and 2C. These findings are further validated by the fact that no fluorescence is seen from negative control wells containing no primary antibody, demonstrating that secondary antibody binding takes place only in the presence of bound primary antibody.

Neural Stem Cell Differentiation

The ability of 3D cultured neural stem cells to differentiate into neurons and glial cells was also evaluated using two separate methods. First, Accutase® cell detachment solution (Corning Cat. No. 25-058-CI) was added to specific wells to break apart neurospheres. Individual neural stem cells were then added to separate wells of a Poly-L-Ornithine/Laminin-coated 384-well high content imaging microplate in the presence of specific media optimized by Corning Life Sciences to differentiate cells into neurons, astrocytes, and oligodendrocytes. Second, whole neurospheres were also transferred to wells of the 384-well microplate containing differentiation medias. Upon completion of prescribed differentiation protocols, immunocytochemistry was again performed including primary antibodies for markers expressed in each lineage (β III-Tubulin: neuron; GFAP: astrocyte; Oligodendrocyte specific protein: oligodendrocyte) and previously described secondary antibodies.

Differentiation into neurons (Figure 3A), astrocytes (Figure 3C), and oligodendrocytes (Figure 3E) was seen from 3D cultured neural stem cells differentiated in 2D format. Neuro- (Figure 3B), astro- (Figure 3D), and oligodendrogenesis (Figure 3F) were also seen from differentiated neurospheres when exposed to the same incubation conditions. The combination of the neurosphere validation experiments confirms that neural stem cells exhibit no ill effects from 3D culture, maintain proliferative multipotency and differentiation capabilities, and represent a suitable model for neurotoxicity testing.

Neurotoxin Analysis

Evaluation of the effect of compounds to cause a toxic effect on 3D neurospheres was then performed. Neural stem cells, at a concentration of 2,000 cells/well, were added to a 384-well spheroid microplate and allowed to aggregate. Neurospheres were then exposed to varying concentrations of three well-known neurotoxins, methylmercury chloride, mercury chloride, and hydrogen peroxide for 1, 2, 4, or 7 days. Spheres were dosed with fresh media and compound daily. Following incubation, media containing compound was removed, wells were washed with fresh media, and media containing total ROS, apoptosis, and live/dead cell probes were added for four hours. Wells were washed 2X with fresh media to remove unbound probe and imaged by the Cytation™ 5 using a 4X objective and DAPI, GFP, RFP, and Texas Red fluorescent imaging channels.




Figure 3. 2D and 3D neural stem cell differentiation. (A) 2D differentiated neurons and (B) 3D neurogenesis; 40x objective; RFP Channel: β III-Tubulin 1° Ab/ ATTO 590 2° Ab; DAPI Channel: Hoechst 33342. (C) 2D differentiated astrocytes, 40X objective and (D) 3D astrogenesis, 20X objective; Texas Red Channel: GFAP 1° Ab/ATTO 647 2° Ab; DAPI Channel: Hoechst 33342. (E) 2D differentiated oligodendrocytes and (F) 3D oligodendrogenesis; 20X objective; Texas Red Channel: oligodendrocyte specific protein 1° Ab/ATTO 647 2° Ab; DAPI Channel: Hoechst 33342; Phase contrast channel overlay also shown in (F).




Figure 4. Image-based cellular analysis of fluorescent probes. 4X images captured following neurotoxin treatment and fluorescent probe incubation. (A) Gen5™ placed object mask around Nuclear-ID live cell probe signal emanating from treated neurosphere captured using DAPI channel. Fluorescent signal from positive or negative control wells treated for four days with 250 or 0 nM hydrogen peroxide, respectively, shown for (B, C) total ROS probe (GFP channel); (D, E) apoptosis detection reagent (RFP channel); and (F, G) dead cell probe (Texas Red channel).

Cellular analysis was then carried out using Gen5™ to accurately detect the signal from each probe emanating from the neurospheres. As the fluorescence from the live cell probe remains relatively consistent despite potential changes in all other probes, this signal as measured with the DAPI channel was used by the software to automatically draw object masks around each neurosphere (Figure 4A). Minimum and maximum object size values were also increased appropriately to allow the spheres to be seen as single objects, as opposed to individual cells. The total fluorescent signal inside the object mask, captured with the GFP, RFP, and Texas Red imaging channels (Figures 4B - 4G), was then calculated to determine the effect each compound treatment had

to change oxidative stress, apoptosis, and necrosis levels, respectively, within 3D cultured neural stem cells.

The images in Figure 4 illustrate how incubation with the known neurotoxicants cause a dramatic increase in signal generated by fluorescent probes when compared to signal from untreated wells. By incorporating cellular analysis, generated object masks focused solely on fluorescence emanating from each neurosphere, eliminating background signal and creating a more sensitive measurement, fold change can then be calculated as previously described. Using this method, the final graphs in Figures 5A and 5B confirm the unmistakable, yet unique, toxic effect that each compound elicits on the 3D neurospheres.





Figure 5. Test compound neurotoxic effect calculation. Fold change in total fluorescent signal calculated by dividing signal from test wells by the average from untreated wells for each specific compound and length of compound incubation. Results shown for (A) total ROS; (B) apoptosis; and (C) fluorescent probes.

Conclusions

- ▶ Neural stem cells cultured into 3D neurospheres with the use of Corning® 384-well spheroid microplates represent a viable, robust cell model that can be easily and consistently created.
- ▶ The configuration of the Corning microplate allows for simple media replacement, compound dosing, and assay performance, in addition to affording the ability to perform cellular imaging in the same microplate.
- ▶ Primary antibodies from Enzo Life Sciences, specific for unique targets, partnered with fluorescently labeled secondary antibodies, provide a sensitive method to assess the presence of essential proteins in cultured neurospheres.
- ▶ Fluorescent probes from Enzo Life Sciences offer a rapid and easily discernible method to detect changes in important toxic biomarkers.
- ▶ The Cytation™ 5 Cell Imaging Multi-Mode Reader affords a sensitive, yet flexible system to perform brightfield, phase contrast, and fluorescent imaging of 2D neural stem cells and 3D neurospheres using a wide range of magnification. Gen5™ Software then supplies the capability to assess changes in multiple whole spheroid analysis parameters to provide accurate results in real time.
- ▶ The combination of the 3D cell model and the microplate, assessment methods, and instrumentation together create a powerful solution to perform accurate, high throughput assessments of the potential neurotoxic effects of test molecules.



www.corning.com/lifesciences/solutions

At Corning, cells are in our culture. In our continuous efforts to improve efficiencies and develop new tools and technologies for life science researchers, we have scientists working in Corning R&D labs across the globe, doing what you do every day. From seeding starter cultures to expanding cells for assays, our technical experts understand your challenges and your increased need for more reliable cells and cellular material.

It is this expertise, plus a 160-year history of Corning innovation and manufacturing excellence, that puts us in a unique position to offer a beginning-to-end portfolio of high-quality, reliable cell culture consumables.

For more specific information on claims, visit the Certificates page at www.corning.com/lifesciences.

Warranty/Disclaimer: Unless otherwise specified, all products are for research use only. Not intended for use in diagnostic or therapeutic procedures. Not for use in humans. Corning Life Sciences makes no claims regarding the performance of these products for clinical or diagnostic applications.

For additional product or technical information, visit www.corning.com/lifesciences or call 800.492.1110. Customers outside the United States, call +1.978.442.2200 or contact your local Corning sales office.

**Corning Incorporated
Life Sciences**

836 North St.
Building 300, Suite 3401
Tewksbury, MA 01876
t 800.492.1110
t 978.442.2200
f 978.442.2476

www.corning.com/lifesciences

**Worldwide
Support Offices**

ASIA/PACIFIC

Australia/New Zealand
t 61 427286832

China
t 86 21 3338 4338
f 86 21 3338 4300

India
t 91 124 4604000
f 91 124 4604099

Japan
t 81 3-3586 1996
f 81 3-3586 1291

Korea
t 82 2-796-9500
f 82 2-796-9300

Singapore
t 65 6572-9740
f 65 6861-2913

Taiwan
t 886 2-2716-0338
f 886 2-2516-7500

EUROPE
France
t 0800 916 882
f 0800 918 636

Germany
t 0800 101 1153
f 0800 101 2427

The Netherlands
t 31 20 655 79 28
f 31 20 659 76 73

United Kingdom
t 0800 376 8660
f 0800 279 1117

**All Other European
Countries**
t 31 (0) 20 659 60 51
f 31 (0) 20 659 76 73

LATIN AMERICA
grupoLA@corning.com
Brasil
t (55-11) 3089-7400
Mexico
t (52-81) 8158-8400



For a listing of trademarks, visit www.corning.com/clstrademarks. All other trademarks are the property of their respective owners.